New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
14:53 EDTARRYArray BioPharma to present positive Phase 2 data on ARRY-797
Array BioPharma announced that an abstract discussing the final Phase 2 trial results with ARRY-797 in patients with osteoarthritis pain will be presented at the 2012 American College of Rheumatology Annual Meeting in Washington, D.C. This abstract includes data on ARRY-797's analgesic effect and markers of disease modification. In addition, biomarkers of cartilage (COMP) and bone (CTX I) degradation were assessed. ARRY 797 treatment resulted in statistically significant decreases in COMP and CTX I at week 4 (decreases of 10% and 38% versus placebo, respectively). The decrease in CTX I was sustained and returned to baseline by the follow up visit. The abstract concludes that further evaluation of the potential for disease modifying activity is warranted.
News For ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
10:11 EDTARRYHigh option volume stocks
Subscribe for More Information
September 28, 2015
12:25 EDTARRYArray data have positive read-through to Phase 3 trial, says Piper Jaffray
Subscribe for More Information
12:22 EDTARRYArray says binimetinib-encorafenib combo shows differentiated tolerability
Subscribe for More Information
September 25, 2015
08:39 EDTARRYArray BioPharma to host conference call
Conference call to discuss preliminary results from two melanoma trials and a colorectal cancer trial will be held on September 28 at 9 am. Webcast Link
September 24, 2015
10:25 EDTARRYOptions with decreasing implied volatility
Options with decreasing implied volatility: HRTX ATML ARRY YY OVTI RHT KMX

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use